Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase III, Randomized, Double-Blind Trial of MK-0431D vs Sitagliptin in Type 2 Diabetes Mellitus
2012-001868-29Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sitagliptin + simvastatin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Merck & Co. Primary endpoints: Change from baseline in HbA1c at Week 16 and Safety and tolerability. Started Sep 2012; status: completed.
02
Drugs
sitagliptin + simvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-001868-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001868-29.